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Abstract
Improvements to contrast media formulations may be an effective way to increase the accuracy 
and effectiveness of thoracic computed tomography (CT) imaging in disease evaluation. To 
achieve contrast enhancement in the lungs, a relatively large localized concentration of contrast 
media must be delivered. Inhalation offers a non-invasive alternative to intrapleural injections for 
local lung delivery, but effective aerosolization may deter successful imaging strategies. Here, 
NanoCluster technology was applied to N1177, a diatrizoic acid derivative, to formulate low 
density nanoparticle agglomerates with aerodynamic diameters ≤ 5 µm. Excipient-free N1177 
NanoCluster powders were delivered to rats by insufflation or inhalation and scanned using CT up 
to 2 h post dose. CT images after inhalation showed a ~120 HU contrast increase in the lungs, 
which was more than sufficient contrast for thoracic CT imaging. Lung tissue histology 
demonstrated that N1177 NanoClusters did not damage the lungs. NanoCluster particle 
engineering technology offers a novel approach to safely and efficiently disseminate high 
concentrations of contrast agents to the lung periphery.
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Introduction
Thoracic computed tomography (CT) imaging has been widely used for visualization of soft 
tissues in the chest, primarily the heart and lungs. For lung damage and disease, CT is 
considered a non-invasive technique for 3D imaging of tumor size and staging in lung 
cancer1–3, for chest injuries and abnormalities in lung size and position1, and for 
determination of fluid collection in diseases such as pneumonia and cystic fibrosis.4 The 
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success of CT imaging in disease diagnosis depends primarily on imaging accuracy. During 
lung cancer prognosis, false positive results can lead to unnecessary and costly further 
testing.5 Although several advancements have been made to imaging techniques, challenges 
still remain to further increase imaging accuracy. Along with advancing imaging 
instrumentation, inaccuracy challenges could be met through the development of improved 
contrast media strategies.
Several compounds have been identified as capable of providing contrast enhancement in 
CT imaging. By far, the most common contrast agent is barium sulfate. Suspensions of 
insoluble barium sulfate are delivered orally for imaging the gastrointestinal tract. However, 
for thoracic imaging, barium sulfate is contraindicated as studies have suggested that barium 
sulfate can cause granulomas, asphyxiation, and could potentially be fatal.6–7 Iodinated 
compounds, such as derivatives of diatrizoic acid, have proved to be safe and effective 
alternatives to barium sulfate as CT contrast agents.3 There are several available iodinated 
contrast agents that are given as intravenous injections for thoracic CT imaging.3 When 
given i.v., however, these compounds are eliminated quickly from the body with insufficient 
amounts of compound localized to the lung. For lung visualization, large local concentration 
is needed to achieve the minimum of 30 Hounsfield units (HU) necessary for contrast 
enhancement.8 Direct delivery may, therefore, be needed to concentrate contrast media to 
the lungs. For example, studies have shown that a >100 HU contrast can be achieved in 
regional lymph nodes after local delivery of iodinated contrast agents (s.c. or i.p. 
injection).9–10
Agents providing improved contrast must be efficiently delivered to increase imaging 
accuracy. To locally deliver contrast agents to the lungs, many studies have focused on 
intrapleural injection, which proves to be very invasive.11–12 Inhalation provides a non-
invasive alternative, if sufficient quantities can be delivered. Surprisingly, very few studies 
have focused on pulmonary delivery of contrast agents to the lungs.8, 13–17 This may be due 
to unsuccessful aerosolization of formulations resulting in low doses and insufficient 
dissemination to the lung periphery. The development of formulations with proper aerosol 
characteristics would facilitate successful strategies for non-invasive delivery of contrast 
agents to the lungs.
Recently, a controlled nanoparticle agglomeration process has been developed that resulted 
in particles with desirable characteristics for inhalation.18–24 These NanoClusters have 
aerodynamic diameters between 1–5 µm, suggesting the powders are capable of deep lung 
deposition in the respiratory bronchioles and alveoli. 6-ethyoxy-6-oxohexyl-3,5-
bis(acetylamino)-2,4,6-triiodobenzoate (N1177) is a water insoluble diatrizoic acid 
derivative that has recently exhibited macrophage uptake after i.v. injection in rabbits.25–27 
N1177 showed promise as an effective contrast agent in those studies and may translate well 
to lung visualization. The NanoCluster particle technology was applied to N1177 to improve 
aerosol entrainment, deposition, and access to the lung periphery. In this study, an excipient-
free NanoCluster formulation was developed for N1177. Particle size analysis and cascade 
impaction data suggested potential deposition of the NanoClusters in the parenchyma. 
Pulmonary delivery of N1177 NanoClusters to rats resulted in a ~120 HU contrast 
enhancement. Histological examination of lung tissue post-inhalation showed no acute lung 
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toxicity compared to normal lung tissue. Overall, the N1177 NanoClusters were successful 




N1177 NanoCluster suspensions were formulated by milling 7 grams of N1177 powder 
(generously provided from NanoScan Imaging, LLC.) in 200 mL distilled water (Barnstead 
International EASYpure® RODI system) for 2 h. A Netzsch MiniCer Media Mill 
(NETZSCH Fine Particle Technology) was operated using YTZ® grinding media (0.5 mm, 
Tosoh Corp.) under an agitation speed of 2,700 rpm. Particle size of NanoCluster 
suspensions was determined by dynamic light scattering (Brookhaven Instruments Corp., 
ZetaPALS) at different time intervals during the milling process. After milling, the collected 
suspension was frozen at −80°C and freeze dried (Labconco FreeZone 1). Drying lasted ~36 
h to remove all appreciable water content. Lyophilized NanoCluster powder was stored in 
glass bottles at room temperature for further use.
Particle size and morphology by scanning electron microscopy (SEM)
The size and morphology of the lyophilized N1177 NanoCluster powder were evaluated 
using an LEO 1550 field emission scanning electron microscope and compared to that of 
N1177 powder as received. Prior to imaging, the samples were sputter-coated with gold for 
3 min.
Chemical stability by HPLC-UV
N1177 chemical stability during NanoCluster formulation was determined by 
chromatographic analysis of N1177 NanoClusters compared to N1177 powder as received. 
The HPLC-UV system consisted of a Shimadzu CBM-20A system controller, LC-10AT 
solvent delivery pump, SPD-10A UV detector, and SIL-10AxL autoinjector. 
Chromatograms were acquired and analyzed using Shimadzu Class vp 7.4 software. A 
Kromasil C18 column (100 × 4.6 mm) was used for separation. An isocratic system was 
used with mobile phase of 65/35 ammonium acetate (25 mM, pH 4.0)/ acetonitrile at a flow 
rate of 1.0 mL/min and detection was performed at 240 nm. Samples of N1177 
NanoClusters and powder as received were made at concentrations of 50 µg/mL in 
acetonitrile and 50 µL of sample was injected on the system. Percent degradation was 
determined using the peak area of the degradant relative to the N1177 peak area.
Thermal analysis by differential scanning calorimetry
The effect of the NanoCluster process on the crystalline state was determined by differential 
scanning calorimetry (DSC). Curves of N1177 NanoClusters and powder as received were 
collected on a Q100 DSC (TA Instruments). Samples (~2.5 mg) were loaded into aluminum 
hermetic pans. Samples were run from 25 to 250°C heating at 10°C/min under dry nitrogen 
at 50 mL/min. Curves were analyzed with Universal Analysis 2000 (version 4.3A) software 
(TA Instruments).
Aillon et al. Page 3























The particle stability of the NanoClusters was determined by measuring the particle size of 
N1177 NanoCluster suspensions subjected to homogenization. Approximately 1 mg of 
powder was suspended in Pluronic®-F127 (BASF) (1 µg/mL) or 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC; Sigma-Aldrich) (13.25 mg/mL), which was used to 
mimic lung surfactant. The particle size of the suspensions was measured by dynamic light 
scattering. The suspensions were diluted with Pluronic®-F127, DPPC, or water until 
measurable by the DLS instrument. The suspensions were then subjected to low speed 
homogenization (5,000 rpm) for 15 sec and then high speed homogenization (25,000 rpm) 
for 15 sec with particle size measurements taken after each. Statistical analysis was 
performed by a t-test at the 95% confidence level.
Aerodynamic size distribution by time-of-flight analysis
The aerodynamic size distribution of the N1177 NanoCluster powder was determined by a 
time-of-flight instrument (Aerosizer; Amherst Process Instruments, Inc.). Approximately 1 
mg of powder was placed in the instrument disperser and particle size measurements were 
acquired over 60 seconds under high shear and feed rate. The instrument size limits were 
0.10–200 µm and particle counts were above 100,000 for all measurements.
Aerosol characterization by cascade impaction
Aerodynamic characteristics of the N1177 NanoClusters as compared to N1177 powder as 
received were analyzed using an Ambient Cascade Impactor (Tisch Environmental, Inc.). 
Approximately 10 mg of powder on a piece of weighing paper was introduced manually to 
the mouthpiece of the impactor, which was operated at ~30 L/min. The cut-off particle 
aerodynamic diameters for each impactor stage were: pre-separator (10.0 µm), stage 0 (9.0 
µm), stage 1 (5.8 µm), stage 2 (4.7 µm), stage 3 (3.3 µm), stage 4 (2.1 µm), stage 5 (1.1 µm) 
stage 6 (0.7 µm), stage 7 (0.4 µm) and filter (0.0 µm). Powder deposited on each impactor 
stage was determined gravimetrically by the difference in weight of filter paper placed on 
each stage before and after powder deposition. The percent emitted fraction (%EF) was 
calculated as the total particle mass collected from the stages of the impactor over the total 
particle mass introduced to the impactor. The fine particle fraction of total dose (FPFTD) was 
determined as the percentage of aerosolized particles that reached the lower seven stages of 
the impactor (aerodynamic diameters < 5.8 µm) or the lower five stages (aerodynamic 
diameters < 3.3 µm).28–29 The mass median aerodynamic diameter (MMAD) and geometric 
standard deviation (GSD) were determined by a linear fit of the cumulative percent less-than 
the particle size range by weight plotted on a probability scale as a function of the logarithm 
of the effective cut-off diameter.30–31
Dry powder insufflation and CT imaging
Male Sprague-Dawley rats (200–250 grams; Charles River Laboratories Inc.) were 
maintained on a 12 h light/dark cycle in humidity and temperature controlled rooms with 
free water and food access. All animal procedures were conducted according to guidelines 
approved by The University of Kansas Institutional Animal Care and Use Committee.
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Rats were anesthetized by a 67.5 mg/kg ketamine, 3.4 mg/kg xylazine and 0.67 mg/kg 
acepromazine subcutaneous cocktail. While under anesthesia, rats were placed on a heating 
pad to maintain a body temperature of 37°C. The rats were then place in an upright 
presentation using a stand made in-house for dosing. N1177 NanoCluster (10 mg) was 
administered by intratracheal insufflation using a Penn-Century DP-4 dry powder 
insufflator. Powder was delivered through the device using 3 mL of air. At the end of the 
experiment, the rats were euthanized by isoflurane inhalation overdose. The thoracic cavity 
was scanned with a Scanco Medical µCT 40 ex vivo scanner with a x-ray tube energy of 45 
kVp.
Aerosol Inhalation and CT imaging
Male Fischer 344 (F344) rats (125–150 grams; Harlan Laboratories, Inc.) were placed in 
restraint tubes and connected to a 24-port-nose-only rodent exposure system (Fig. 1). N1177 
NanoCluster aerosols were generated with a Palas 1000 Rotating Brush Generator (RBG) 
with an outlet flow of ~19 L/min and delivered through a stainless-steel aerosol delivery line 
into the rodent exposure system with an equivalent exhaust. Rats inhaled the generated 
aerosols for 21.5 min. Aerosol concentration was measured at the rodent exposure chamber 
by collection onto pre-weighed 47-mm Pallflex membrane filters (Type T60A20, Pall 
Gelman Sciences). Filters were analyzed via differential weight analysis. Particle size was 
measured at the rodent exposure chamber with an aerodynamic particle sizer (TSI Model 
3321) (Fig. 1).
Each rat was imaged before and 2 h post exposure on a NanoSPECT/CT (Bioscan, Inc.). An 
initial whole body topogram was taken to determine the region containing the entire lung 
volume, with a typical length of ~40 mm. Each image was acquired using the Ultrafine 
setting, allowing maximum resolution upon reconstruction. Each acquisition was 6 min long 
with a x-ray tube energy of 65 kVp and 1000 mAs.
CT data analysis
CT image analysis was performed by Kitware, Inc. After visual inspection of the scans 
before and 2 h after dose, the mean Hounsfield unit (HU) density for the full lung 
parenchyma was measured using a 2D contour drawing tool.
Lung tissue toxicity determination
After CT imaging and animal euthanasia, the lungs were removed and stored in 10% neutral 
buffered formalin. Tissue samples were taken to a hospital pathology lab for histology 
processing. Tissue sections representing all depths of the lung were embedded in paraffin 
wax and the slices from the tissues were stained with hematoxylin and eosin (H and E) dyes. 
The results were compared to normal lung histology and the toxicity results were discussed 
with a pathologist.
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N1177 NanoClusters can be successfully formulated by a wet milling procedure
Since large doses of iodinated contrast agents are typically needed to achieve the minimum 
required contrast enhancement, a wet milling procedure was selected to formulate the N1177 
contrast agent to enable larger batch processing. Using this technique, excipient-free N1177 
NanoClusters were successfully created. Formulations containing only the contrast agent 
without additives reduce the total dose necessary to achieve needed contrast enhancement.
To track the media milling time needed to achieve the appropriate particle size, drug 
suspension samples were collected at discrete intervals during milling. N1177 particles 
decreased in size within 30 min followed by an increase in size over 2 h (Table 1). During 
this process, fine hydrophobic nanoparticles were not observed in suspension, but rather 
assembled into low density agglomerates (i.e. NanoClusters). Particle size, density, and 
morphology were determined using other techniques.
Scanning electron microscopy revealed differences in the morphology of the unprocessed 
N1177 powder as received and the N1177 NanoClusters. The unprocessed N1177 appeared 
as micronized faceted particles (Fig. 2A), while images of the NanoClusters showed small 
nanoparticles (~300 nm) agglomerated into micron-sized clusters (Fig. 2B). Fine 
nanostructure was retained in the NanoClusters creating a porous matrix that could aid in the 
aerosolization of the dried particles.
Compound and particle stability are retained after formulation into NanoClusters
To verify the chemical stability of N1177 during NanoCluster formulation, HPLC-UV 
chromatograms of N1177 NanoClusters were compared to N1177 as received (Fig. 3). For 
both NanoClusters and powder as received, N1177 had a retention time of 8.3 min. The only 
observable difference between the two chromatograms was a 5-fold increase in peak at a 
retention time of 2.7 min in the NanoClusters chromatogram. This potential degradant peak 
had a peak area of less than 1% of the N1177 peak. Based on the similarities of the 
chromatograms, it was concluded that N1177 NanoClusters retained ≥ 99% of the native 
structure during the formulation process.
DSC thermograms of N1177 NanoClusters as compared to powder as received showed no 
differences in the crystalline state of N1177 during the NanoCluster formulation. For the 
powder as received, an endotherm was observed at 198°C followed by N1177 degradation at 
240°C. N1177 NanoClusters also exhibited the endotherm characteristic to N1177, but at 
182°C with subsequent compound degradation at 235°C. This shift in temperature has been 
observed with other compounds formulated into NanoClusters as well as other types of 
formulations with reduced particle size18, 24, 32–33. Therefore, it was concluded that the shift 
in endotherms for N1177 NanoClusters was due to N1177 size reduction during formulation.
NanoCluster particles have the potential to disperse after lung deposition. To probe physical 
stability, NanoClusters were suspended in Pluronic®-F127 surfactant or DPPC and 
subjected to low and high speed homogenization. DLS measurements of the suspension 
before and after each homogenization showed no significant difference between the particle 
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size measured before and after low speed homogenization in Pluronic®-F127 (Table 2). 
Under extreme shear (homogenization at 25,000 rpm) the particle size decreased to half the 
original diameter (Table 2). N1177 NanoClusters suspended in DPPC showed no significant 
difference in particle size measured under all conditions, which indicated the NanoClusters 
particles are likely to maintain their micro-structure under physiological conditions.
N1177 NanoClusters have proper aerosol characteristics for deep lung deposition
The aerodynamic size distribution of the N1177 NanoClusters was determined using time-
of-flight analysis. The distribution of the NanoClusters was monodispersed (Fig 5A). The 
median aerodynamic diameter (MAD) was 1.6 µm and 95% of the powder was found to be 
below 5.3 µm. This data supports that the NanoClusters have the aerodynamic particle size 
desirable for deposition in the lung periphery. In comparison, the N1177 powder as received 
showed a MAD of 3.1 µm. Therefore, formulating N1177 into NanoClusters resulted in a 
lower MAD (i.e. a higher fraction of fine particles).
Cascade impaction studies were performed for N1177 NanoCluster powder and compared 
with that of N1177 powder as received. N1177 NanoClusters were mainly deposited in the 
third stage (3.3 µm). A substantial fraction of fine particles (< 5 µm) was observed. N1177 
powder as received deposited mainly in the preseparator and zero stage (9.0 µm) (Fig. 5B). 
The high emitted fraction of dry powders obtained at the tested flow rate (~85%) and the 
results of the fine particle fraction suggested efficient aerosolization of the NanoClusters 
(Table 2). The mass median aerodynamic diameter (MMAD) of N1177 NanoCluster dry 
powders was ~4.2 µm. The geometric standard deviation (GSD) was determined from the 
following equation34:
where dn is the diameter at the nth percentile of the cumulative distribution. The GSD was 
found to be ~2, suggesting particles were relatively monodispersed (Table 2).18–19
Aerosolization of N1177 NanoClusters offers lung contrast enhancement
Local delivery of N1177 NanoClusters by dry powder insufflation into rats dramatically 
enhanced image contrast of the lung airways. The trachea and bronchi were clearly seen in 
the 3D reconstructed CT images taken directly after insufflation (Fig. 6A). More 
importantly, visualization of the respiratory bronchioles and some alveolar structures in the 
lung periphery were evident, confirming deep lung deposition of the NanoClusters. After 2 h 
(Fig. 6B), the contrast agent cleared from the central airways with contrast more localized to 
the trachea or lung periphery. This suggested that the compound may be further 
concentrating in the lung periphery over the course of 2 h. Although a large portion of the 
dose was visibly deposited in the trachea after insufflation, visualization of the entire airway 
was improved with the N1177 NanoClusters. It is important to note that insufflation delivery 
was performed by quickly forcing a burst of 3 mL of air through the insufflator device 
which then dispensed the compound into the lungs. With this method, compound was 
forcibly delivered to the lungs with favored deposition to the right lung due to anatomical 
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positioning; branching to the right lung being more vertically aligned. This delivery 
technique, therefore, is not representative of compound deposition in the lung after aerosol 
inhalation and may account for some of the observed powder in the upper respiratory tract 
and enhanced contrast in the right lung.
To better aerosolize the N1177 NanoClusters using a more clinically relevant delivery 
method, pulmonary delivery was conducted using passive, nose-only inhalation of generated 
aerosols (Fig. 1). Aerosol concentrations measured at the rodent exposure chamber showed 
1.04 mg/mL N1177 NanoClusters were maintained in the chamber and delivered to the rats 
for 21.5 min. Particle size measurements by dynamic light scattering revealed that the 
generated aerosols had a MAD of 1.1 µm (GSD = 1.6) within the aerosolization chamber. 
Analysis of the CT images revealed a 118 HU difference between the images taken prior to 
dosing (−620 HU) and 2 h post inhalation (−502 HU) (Fig. 7). This excellent contrast 
enhancement was well above the 30 HU minimum needed for contrast.8 Lower doses could 
potentially be explored to reduce the amount of contrast agent that would need to be 
delivered.
N1177 NanoClusters exhibited no acute lung toxicity when inhaled
Several sections of lung tissue representing all depths of the lung were sliced for histological 
examination. Lung tissue from the aerosol inhalation studies revealed no inflammatory 
response from the N1177 NanoClusters (Fig. 8A). In comparison to normal lung tissue (Fig. 
8C), no differences were observed and an increase in macrophages was not evident. Lung 
tissue histology from rats dosed by dry powder insufflation revealed a mild hemorrhagic 
response (Fig. 8B). This response was most likely due to the focal deposition of highly 
concentrated contrast agent in discrete lung regions. During the insufflation method, N1177 
was propelled at high doses into confined regions whereby the large amounts of contrast 
agent most likely elicited the inflammatory response. Although there were regions of 
inflammation after insufflation, the majority of the lung tissue presented no inflammatory 
response. Accompanying the hemorrhagic response was the presence of macrophage clusters 
in the alveolar sacs. Previously, studies of N1177 nanoparticles showed macrophage uptake 
after i.v. administration followed by transit to regional lymph nodes.25–27 It is probable, 
therefore, that alveolar macrophage clusters present in the lung after insufflation may 
transport N1177 to lung lymph nodes. For both delivery methods, the effects of N1177 
NanoClusters over a longer period of time will be important to determine inflammation and 
to better characterize the regional transport of N1177.
Conclusions
Aerosolized contrast media may provide a non-invasive means to localize contrast agents to 
the lungs to improve thoracic CT imaging accuracy for lung disease and damage diagnosis. 
Deposition of contrast agents to the lung periphery, however, can be complicated by 
formulations with undesirable aerosol performance. In this study, a diatrizoic acid 
derivative, N1177, was formulated using NanoCluster technology, a unique and simple 
method to create an inhalable, excipient-free dry powder contrast agent. Particle 
characterization revealed that the NanoClusters had desirable aerosol characteristics and 
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offered a fine particle fraction suitable for deposition in the lung periphery. After pulmonary 
delivery to rats, a substantial contrast enhancement of 118 HU was achieved. Additionally, 
lung tissue histological examination revealed that no acute lung toxicity was associated with 
the N1177 NanoClusters after inhalation. Overall, the N1177 NanoClusters were capable of 
deposition in the lung periphery with exceptional contrast enhancement for lung 
visualization by thoracic CT imaging.
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Schematic of the 24-port nose-only rodent inhalation delivery system.
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Scanning electron micrographs of N1177 particles: (A) unprocessed N1177 as received and 
(B) N1177 NanoClusters.
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Chromatograms of N1177 NanoClusters compared to N1177 powder as received. The inset 
highlights the potential degradant peak (retention time = 2.718 min).
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DSC thermograms of N1177 NanoClusters and N1177 powder as received.
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The aerodynamic size distribution of N1177 NanoCluster powder determined by (A) time-
of-flight and (B) cascade impaction.
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3D reconstructed CT images of rat thoracic cavities after 10 mg N1177 NanoCluster dry 
powder insufflation A) directly after dose and B) 2 h post dose. N1177 NanoCluster shown 
in green and soft tissue shown in pink.
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CT image transverse cross sections of rat lungs A) before dose and B) after N1177 
Nanocluster aerosol inhalation. The region of interest used for calculating contrast is 
outlined.
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Rat lung tissue histology A) 2 h after aerosol inhalation of N1177 NanoClusters, B) 2 h after 
insufflation of N1177 NanoClusters, and C) normal lung tissue
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Table 1
N1177 particle size over time during media milling (values = average ± S.D.).
Time (min) Particle size (nm)
15 1430 ± 1
30 660 ± 5
45 823 ± 2
60 880 ± 2
90 1068 ± 0.4
120 1200 ± 3
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Table 2
Particle size measured from DLS before and after low and high speed homogenization of N1177 NanoCluster 
suspensions (in Pluronic®-F127 or DPPC) (values = average ± S.D.).
Particle size (nm)
Pluronic®-F127 DPPC
Before homogenization 1433.4 ± 194.4 847.9 ± 206.5
Low speed homogenization 979.2 ± 122.0 781.8 ± 55.3
High speed homogenization 500.3 ± 21.7** 614.7 ± 92.6
**
p < 0.05
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Table 3
Cascade impaction results of lyophilized N1177 NanoCluster dry powder (NC) at 30 L/min (values = average 
± S.D.).
Powder properties N1177 NC N1177 powder as
received
At flow rate of ~30 L/min % EFa 85 ± 5 70 ± 5
% FPFb < 5.7 µm 75 ± 1 7 ± 3
< 3.3 µm 22 ± 1 2 ± 1
MMAD (µm)c 4.2 ± 0.1 8.6 ± 0.3
GSDd 2 ± 0.2 2.3 ± 0.5
a
% EF: Percent emitted fraction
b
FPF: Fine particle fraction
c
MMAD: Mass median aerodynamic diameter
d
GSD: Geometric standard deviation
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